The University of Southampton
University of Southampton Institutional Repository

Treatment of influenza with neuraminidase inhibitors

Treatment of influenza with neuraminidase inhibitors
Treatment of influenza with neuraminidase inhibitors
PURPOSE OF REVIEW:

Seasonal and pandemic influenza are major causes of morbidity and mortality globally. Neuraminidase inhibitors (NAIs) are the only class of antiviral agent recommended for the treatment of currently circulating strains of influenza. There has previously been controversy over the level of evidence for patient benefit with NAIs. We review here the current evidence base for the clinical impact of treatment of influenza with NAIs.

RECENT FINDINGS:

Meta-analysis of pharma-sponsored studies (including previously unpublished data) shows that NAIs reduce the duration of illness in influenza-infected patients, and suggest a possible reduction in the rate of complications and hospitalization. Meta-analysis of observational studies examining oseltamivir use during the H1N1 2009 pandemic, suggest a reduction in hospitalization rate in community-dwelling patients and a reduction in mortality in hospitalized adults treated with NAIs. Current NAI use in the community and hospitals varies widely but in general they are underutilized.

SUMMARY:

Although there has been controversy over the level of evidence for patient benefit, a growing body of evidence suggests that treatment of influenza with NAIs is associated with improved outcomes for both patients in the community and more severely unwell patients in hospital. Clinical outcomes are optimal with earlier use and strategies to improve early widespread NAI utilization are needed.
0951-7375
514-519
Beard, Kate
85604fec-3541-48cb-9abf-a76c2a32c3f1
Brendish, Nathan, James
d07b588f-4919-456d-8604-04efde7711fd
Clark, Tristan
712ec18e-613c-45df-a013-c8a22834e14f
Beard, Kate
85604fec-3541-48cb-9abf-a76c2a32c3f1
Brendish, Nathan, James
d07b588f-4919-456d-8604-04efde7711fd
Clark, Tristan
712ec18e-613c-45df-a013-c8a22834e14f

Beard, Kate, Brendish, Nathan, James and Clark, Tristan (2018) Treatment of influenza with neuraminidase inhibitors. Current opinion in infectious diseases, 31 (6), 514-519. (doi:10.1097/QCO.0000000000000496).

Record type: Article

Abstract

PURPOSE OF REVIEW:

Seasonal and pandemic influenza are major causes of morbidity and mortality globally. Neuraminidase inhibitors (NAIs) are the only class of antiviral agent recommended for the treatment of currently circulating strains of influenza. There has previously been controversy over the level of evidence for patient benefit with NAIs. We review here the current evidence base for the clinical impact of treatment of influenza with NAIs.

RECENT FINDINGS:

Meta-analysis of pharma-sponsored studies (including previously unpublished data) shows that NAIs reduce the duration of illness in influenza-infected patients, and suggest a possible reduction in the rate of complications and hospitalization. Meta-analysis of observational studies examining oseltamivir use during the H1N1 2009 pandemic, suggest a reduction in hospitalization rate in community-dwelling patients and a reduction in mortality in hospitalized adults treated with NAIs. Current NAI use in the community and hospitals varies widely but in general they are underutilized.

SUMMARY:

Although there has been controversy over the level of evidence for patient benefit, a growing body of evidence suggests that treatment of influenza with NAIs is associated with improved outcomes for both patients in the community and more severely unwell patients in hospital. Clinical outcomes are optimal with earlier use and strategies to improve early widespread NAI utilization are needed.

Text
COID NAIs TWC - Accepted Manuscript
Restricted to Repository staff only until 12 October 2019.
Request a copy

More information

Accepted/In Press date: 19 September 2018
e-pub ahead of print date: 12 October 2018
Published date: 17 October 2018

Identifiers

Local EPrints ID: 425435
URI: https://eprints.soton.ac.uk/id/eprint/425435
ISSN: 0951-7375
PURE UUID: 3e65dcc4-19ae-44a8-b545-53fcba03cb81
ORCID for Nathan, James Brendish: ORCID iD orcid.org/0000-0002-9589-4937
ORCID for Tristan Clark: ORCID iD orcid.org/0000-0001-6026-5295

Catalogue record

Date deposited: 19 Oct 2018 16:30
Last modified: 14 Mar 2019 01:33

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×